MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-22-2026
Quest Diagnostics Incorporated Revenue 2011-2026 | DGX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Quest Diagnostics Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11 B | 9.87 B | 9.25 B | 9.88 B | 10.8 B | 9.44 B | 7.73 B | 7.53 B | 7.71 B | 7.52 B | 7.49 B | 7.44 B | 7.15 B | 7.38 B | 7.51 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11 B | 7.15 B | 8.51 B |
Quarterly Revenue Quest Diagnostics Incorporated
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.9 B | 2.82 B | 2.76 B | 2.65 B | 2.49 B | 2.4 B | 2.37 B | 2.3 B | 2.34 B | 2.33 B | - | 2.49 B | 2.45 B | 2.61 B | - | 2.77 B | 2.55 B | 2.72 B | 3 B | 2.79 B | 1.83 B | 1.82 B | 1.93 B | 1.96 B | 1.95 B | 1.89 B | 1.84 B | 1.89 B | 1.92 B | 1.88 B | 1.86 B | 1.86 B | 1.86 B | 1.82 B | 1.86 B | 1.88 B | 1.91 B | 1.86 B | 1.85 B | 1.88 B | 1.92 B | 1.84 B | 1.88 B | 1.9 B | 1.9 B | 1.75 B | 1.76 B | 1.79 B | 1.82 B | 1.79 B | 1.77 B | 1.82 B | 1.88 B | 1.91 B | 1.85 B | 1.91 B | 1.9 B | 1.82 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3 B | 1.75 B | 2.1 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
6.32 B | $ 116.23 | 0.6 % | $ 35.3 B |  USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Co-Diagnostics
CODX
|
622 K | $ 1.67 | - | $ 2.22 M | USA |
 |
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 25.26 | 3.27 % | $ 702 M | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 21.52 | 1.37 % | $ 1.15 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | USA |
 |
Illumina
ILMN
|
4.37 B | $ 127.89 | 0.01 % | $ 20.3 B | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 16.19 | -0.74 % | $ 490 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 172.96 | 1.88 % | $ 8.57 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Guardant Health
GH
|
982 M | $ 90.69 | 2.0 % | $ 11.4 B | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 84.36 | 0.04 % | $ 5.69 B | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 416.53 | 1.46 % | $ 12 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
38.7 M | $ 2.0 | 1.27 % | $ 8.85 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 27.72 | 0.91 % | $ 20 B |  Niderland |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
Senseonics Holdings
SENS
|
35.3 M | $ 7.07 | 0.21 % | $ 295 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B | Niderland |
 |
Neogen Corporation
NEOG
|
895 M | $ 9.6 | 0.58 % | $ 2.08 B | USA |
 |
Soleno Therapeutics
SLNO
|
190 M | $ 52.74 | 0.04 % | $ 2.68 B | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 2.17 | 1.4 % | $ 4.98 M | USA |
 |
National Research Corporation
NRC
|
137 M | $ 17.26 | 0.17 % | $ 386 M | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 102.05 | -0.12 % | $ 8.42 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 265.38 | 0.62 % | $ 22.1 B | USA |
 |
Thermo Fisher Scientific
TMO
|
44.6 B | $ 470.88 | 0.28 % | $ 178 B | USA |
 |
Trinity Biotech plc
TRIB
|
61.6 M | $ 0.65 | 0.03 % | $ 61.9 M | Irlanda |
 |
OpGen
OPGN
|
5.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
NeoGenomics
NEO
|
727 M | $ 8.43 | 1.69 % | $ 1.08 B | USA |
 |
Twist Bioscience Corporation
TWST
|
377 M | $ 60.75 | -0.31 % | $ 3.63 B | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 4.79 | 0.1 % | $ 444 M | USA |
 |
Natera
NTRA
|
820 M | $ 206.25 | 1.23 % | $ 20.3 B | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
PerkinElmer
PKI
|
2.86 B | - | -0.91 % | $ 14.7 B | USA |